Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online. "These presentations reflect Acumen's commitment to understanding the biology of early AD as well as the full experience, including the perspectives of patients and care partners living with it every day," said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. "These important insights from our study collaborators and participants in ALTITUDE-AD help keep their needs at the center of our efforts to advance sabirnetug as a potential treatment of choice for AD."

Acumen's presentation details are as follows:

Topic: P015 ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer's disease

Date/Time: Monday, November 16, 2:00 p.m. - Tuesday, November 17, 5:30 p.m. EST
Format: Poster Presentation
Session: Poster Session 1
Presenting Author: Linda Pao, MD, Medical Director and Principal Investigator, JEM Research Institute

Topic: P023 ALTITUDE-AD: Qualitative interviews assessing treatment expectations and motivations for clinical trial participation in early Alzheimer's disease

Date/Time: Monday, November 16, 2:00 p.m. - Tuesday, November 17, 5:30 p.m. EST
Format: Poster Presentation
Session: Poster Session 1
Presenting Author: Stephanie Cline, PhD, Health Outcomes Consultant, Acumen Pharmaceuticals

Topic: P024 Perspectives on the care experience in early Alzheimer's: Narratives from study partners in the ALTITUDE-AD clinical trial

Date/Time: Monday, November 16, 2:00 p.m. - Tuesday, November 17, 5:30 p.m. EST
Format: Poster Presentation
Session: Poster Session 1
Presenting Author: Stephanie Cline, PhD, Health Outcomes Consultant, Acumen Pharmaceuticals

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer's disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in late 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic AD, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD™)-enabled therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "should," "would," "seeks," "aims," "plans," "potential," "will," "milestone" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business and the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193).. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
ICR Healthcare
AcumenPR@icrhealthcare.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS
The Conversation (0)
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesityEvotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomicsLille University... Keep Reading...

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalents and marketable... Keep Reading...

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C.... Keep Reading...

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank... Keep Reading...

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug... Keep Reading...
Metalsource Mining Announces Management Transition as Silver Hill Exploration Advances

Metalsource Mining Announces Management Transition as Silver Hill Exploration Advances

Dale Moore continues to guide drilling operations as Tom Kleeberg transitions to a consulting role.Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) ("Metalsource" or the "Company") announces a management transition that maintains continuity across its technical and operational teams... Keep Reading...
Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District

Steadright Begins Exploration at Péribonka Ree-Niobium Carbonatite Target in Quebec's Niobium District

(TheNewswire) NSM CAPITAL SARL AMENDMENT APPROVED Muskoka, Ontario TheNewswire - November 12, 2026 Steadright Critical Minerals Inc. (CSE: SCM) ("Steadright" or "SCM") is pleased to announce that exploration is underway at the Péribonka Rare Earth Element (REE) and Niobium Carbonatite Target... Keep Reading...
Red Metal Reports Mine Sampling at Farellon, Including 6.8% Copper on Level 7 and 6.05% Copper on Level 9

Red Metal Reports Mine Sampling at Farellon, Including 6.8% Copper on Level 7 and 6.05% Copper on Level 9

Red Metal Resources Ltd. (CSE: RMES) (OTC: RMESF) (FSE: I660) ("Red Metal" or the "Company") is pleased to report assay results for 21 rock samples collected by the Company from the underground workings and run-of-mine ("ROM") ore stockpiles at the Farellon Project, part of its Carrizal... Keep Reading...
Nuvau Intersects 76.23 g/t Au over 0.5 Metres

Nuvau Intersects 76.23 g/t Au over 0.5 Metres

Additional drilling at Thundermine, Matagami further defines broad mineralization and high grade vein potential Results from three additional holes at Nuvau Minerals Inc.'s (TSXV: NMC) Thundermine target reinforce the emerging model of an orogenic gold system hosted in felsic intrusive rocks.... Keep Reading...
Renforth Completes Additional Channel Sampling On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

Renforth Completes Additional Channel Sampling On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

(TheNewswire) TORONTO, Ontario — November 12, 2026 — TheNewswire - Renforth Resources Inc. (CSE: RFR,OTC:RFHRF | OTC: RFHRF | FSE: 9RR) ("Renforth" or the "Company") is pleased to advise shareholders that it has completed additional channel sampling within the stripped area of the open-pit shell... Keep Reading...
Multiple Chalice Style Gold Targets Identified

Multiple Chalice Style Gold Targets Identified

Corazon Mining (CZN:AU) has announced Multiple Chalice Style Gold Targets IdentifiedDownload the PDF here. Keep Reading...

Interactive Chart

Latest Press Releases

Related News